Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Apr 10;28(13):2911–2922. doi: 10.1158/1078-0432.CCR-21-1643

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

©2022 The Authors; Published by the American Association for Cancer Research

This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license.

PMC Copyright notice

Figure 2. Clinical features and mutational landscape of early-stage and late-stage cohorts. A, Diagnosis age [median 61.3 years (early stage), 62.3 years (late stage); P = NS]. B, Overall survival. Median 60.3 months for late stage, and not reached for early stage. Log-rank. HR, 0.13 (95% CI, 0.07–0.26), P < 0.0001 (Log-rank). C, Short variants (SNV and indels) for each patient in early-stage and late-stage cohorts. The top plot shows the number of mutations in each tumor sample. D, Gene mutation mapper plot of TP53 in early-stage cohort and (E) late-stage cohort. Key hotspot residues are marked. The commonest residue mutations in each cohort are marked in red. — Clinical features and mutational landscape of early-stage and late-stage cohorts. A, Diagnosis age [median 61.3 years (early stage), 62.3 years (late stage); P = NS]. B, Overall survival. Median 60.3 months for late stage, and not reached for early stage. Log-rank. HR, 0.13 (95% CI, 0.07–0.26), P < 0.0001 (Log-rank). C, Short variants (SNV and indels) for each patient in early-stage and late-stage cohorts. The top plot shows the number of mutations in each tumor sample. D, Gene mutation mapper plot of TP53 in early-stage cohort and (E) late-stage cohort. Key hotspot residues are marked. The commonest residue mutations in each cohort are marked in red.